Supplementary Table 5. Summary of efficacy outcomes at weeks 52 and 116 in the ITT population who received ≥1 dose of IXE (observed and imputed)

	Efficacy population (N=932) (Weeks 0-116)											
	PBO/IXE N=272				ADA/IXE N=86				IXE N=574			
	Week 52		Week 116		Week 52		Week 116		Week 52		Week 116	
Response: n/N (%)	**Observed**	**Imputed**	**Observed**	**Imputed**	**Observed**	**Imputed**	**Observed**	**Imputed**	**Observed**	**Imputed**	**Observed**	**Imputed**
ASAS20	165/252 (65.5)	165/272 (60.7)	150/207 (72.5)	150/272 (55.1)	58/81 (71.6)	58/86 (67.4)	52/70 (74.3)	52/86 (60.5)	341/496 (68.8)	341/574 (59.4)	311/413 (75.3)	311/574 (54.2)
ASAS40	113/252 (44.8)	113/272 (41.5)	116/207 (56.0)	116/272 (42.6)	44/81 (54.3)	44/86 (51.2)	39/70 (55.7)	39/86 (45.3)	247/496 (49.8)	247/574 (43.0)	235/413 (56.9)	235/574 (40.9)
CRP <5 mg/L	169/248 (68.1)	169/272 (62.1)	144/205 (70.2)	144/272 (52.9)	63/80 (78.8)	63/86 (73.3)	55/70 (78.6)	55/86 (64.0)	343/487 (70.4)	343/574 (59.8)	302/407 (74.2)	302/574 (52.6)
ASDAS ID (<1.3)	32/248 (12.9)	32/272 (11.8)	33/207 (15.9)	33/272 (12.1)	15/80 (18.8)	15/86 (17.4)	12/70 (17.1)	12/86 (14.0)	79/487 (16.2)	79/574 (13.8)	71/413 (17.2)	71/574 (12.4)
ASDAS LDA (<2.1)	92/248 (37.1)	92/272 (33.8)	96/207 (46.4)	96/272 (35.3)	41/80 (51.3)	41/86 (47.7)	41/70 (58.6)	41/86 (47.7)	222/487 (45.6)	222/574 (38.7)	203/413 (49.2)	203/574 (35.4)
BASDAI50	109/252 (43.3)	109/272 (40.1)	103/207 (49.8)	103/272 (37.9)	39/81 (48.1)	39/86 (45.3)	38/70 (54.3)	38/86 (44.2)	221/496 (44.6)	221/574 (38.5)	215/413 (52.1)	215/574 (37.5)
ASDAS clinically important improvement	147/248 (59.3)	147/272 (54.0)	138/207 (66.7)	138/272 (50.7)	55/80 (68.8)	55/86 (64.0)	45/70 (64.3)	45/86 (52.3)	307/487 (63.0)	307/574 (53.5)	284/413 (68.8)	284/574 (49.5)
ASDAS major improvement	76/248 (30.6)	76/272 (27.9)	79/207 (38.2)	79/272 (29.0)	28/80 (35.0)	28/86 (32.6)	25/70 (35.7)	25/86 (29.1)	170/487 (34.9)	170/574 (29.6)	154/413 (37.3)	154/574 (26.8)
Change from baseline: mean (SD; n)												
ASDAS	-1.49 (1.15; 248)		-1.72 (1.16; 205)		-1.59 (1.07; 80)		-1.64 (1.06; 70)		-1.56 (1.12; 487)		-1.69 (1.13; 407)	
BASDAI	-2.90 (2.28; 252)		-3.33 (2.24; 207)		-3.12 (2.27; 81)		-3.33 (2.24; 70)		-3.14 (2.36; 496)		-3.43 (2.33; 413)	
BASDAI inflammation[a]	-3.05 (2.50; 252)		-3.42 (2.51; 207)		-3.37 (2.38; 81)		-3.61 (2.40; 70)		-3.43 (2.63; 496)		-3.69 (2.50; 413)	
CRP (mg/L)	-11.39 (24.71; 248)		-12.97 (25.04; 205)		-9.96 (17.46; 80)		-10.42 (18.60; 70)		-9.45 (20.19; 487)		-10.79 (21.94; 407)	
PatGA	-3.02 (2.83; 252)		-3.49 (2.69; 207)		-3.21 (2.72; 81)		-3.51 (2.77; 70)		-3.25 (2.72; 496)		-3.48 (2.70; 413)	
BASFI	-2.45 (2.41; 252)		-3.00 (2.42; 207)		-2.73 (2.31; 81)		-2.95 (2.39; 70)		-2.79 (2.53; 496)		-3.04 (2.50; 413)	
BASMI	-0.48 (0.91; 252)		-0.52 (0.87; 203)		-0.60 (0.92; 81)		-0.67 (0.99; 70)		-0.52 (0.95; 496)		-0.57 (0.98; 410)	
ASAS HI	-2.69 (3.56; 252)		-3.07 (3.53; 207)		-3.00 (3.68; 81)		-3.14 (3.49; 70)		-3.27 (3.63; 496)		-3.42 (3.92; 412)	
SF-36 PCS	7.48 (8.22; 252)		8.32 (8.56; 207)		7.87 (7.88; 81)		7.65 (7.63; 70)		9.04 (8.70; 496)		9.61 (9.10; 412)	
Spinal pain due to AS	-3.22 (2.62; 252)		-3.66 (2.57; 207)		-3.36 (2.43; 81)		-3.51 (2.37; 70)		-3.45 (2.72; 496)		-3.71 (2.62; 413)	

Spinal pain at night due to AS	-3.38 (2.81; 252)	-3.71 (2.76; 207)	-3.69 (2.66; 81)	-4.04 (2.65; 70)	-3.63 (2.80; 496)	-3.83 (2.68; 413)

Baseline was defined as Week 0 of originating study.

[a]Mean of BASDAI questions 5 and 6

Abbreviations: ADA, adalimumab; ASAS, Assessment of Spondyloarthritis International Society; ASASx, x% improvement of ASAS criteria; ASAS HI, Assessment of Spondyloarthritis International Society Health Index, ASDAS, Ankylosing Spondylitis Disease Activity Score; bDMARD, biologic disease-modifying anti-rheumatic drug; CRP, C-reactive protein; ID, inactive disease; ITT, intent-to-treat; IXE, ixekizumab; PatGA, Patient Global Assessment of Disease Activity; LDA, low activity disease; MCS, Mental Component Score; PBO, placebo; PCS, Physical Component Score; SF-36, 36-item Questionnaire Short-Form Health Survey; TNFi, tumour necrosis factor inhibitor; Q2W, every 2 weeks; Q4W, every 4 weeks.